Risk of ventricular arrhythmia with citalopram and escitalopram: A population-based study

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Qirjazi, Elena ^a   McArthur, Eric ^b   Nash, Danielle M ^b   Dixon, Stephanie N ^a,b   Weir, Matthew A ^a   Vasudev, Akshya ^a   Jandoc, Racquel ^b   Gula, Lorne J ^a   Oliver, Matthew J ^c   Wald, Ron ^d,e   Garg, Amit X ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; PAROXETINE; SERTRALINE; SEROTONIN UPTAKE INHIBITOR;

AGED; ARTICLE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; CANADA; CHEMICALLY INDUCED; RISK FACTOR; TACHYCARDIA, VENTRICULAR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CANADA; CITALOPRAM; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; TACHYCARDIA, VENTRICULAR;

EID: 84983488569     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0160768     Document Type: Article

References (54)

1. Newman SC, Schopflocher D. Trends in antidepressant prescriptions among he elderly in Alberta during 1997 to 2004. Can J Psychiatry 2008; 53(10):704-7. PMID: 18940040
2. Mamdani MM, Parikh SV, Austin PC, Upshur RE. Use of antidepressants among elderly subjects: Trends and contributing factors. Am. J Psychiatry 2000; 157(3):360-7. PMID: 10698810
3. Petersen T, Dording C, Neault NB, Kombluh R, Alpert JE, Nierenberg AA, et al. A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Bio Psychiatry 2002; 26(1):177-87.
4. IMS Institute for Health Informatics.The use of medicines in the United States: review of 2011.
5. Czaja AS, Valuck RJ, Anderson HD. Comparative safety of selective serotonin reuptake inhibitors among pediatric users with respect to adverse cardiac events. Pharmacoepidemiol Drug Saf 2013; 22 (6):607-15. PMID: 23456956
6. Patel NH, Golwala H, Stavrakis S, Schechter E. Sertraline-induced ventricular tachycardia. Am J Ther 2013; 20(6):e720-2. doi: 10.1097/MJT.0b013e3182192d6e PMID: 21768871
7. Tseng PT, Lee Y, Lin YE, Lin PY. Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review. Gen Hosp Psychiatry 2012; 34(210):e13-15.
8. Vieweg WV, Hasnain M, Howland RH, Hettema JM, Kogut C, Wood MA, et al. Citalopram, QTc interval prolongation and torsade de pointes. How should we apply the recent FDA ruling? Am J Med 2012; 125 (9):859-68. doi: 10.1016/j.amjmed.2011.12.002 PMID: 22748401
9. de Gregorio C, Morabito G, Cerrito M, Dattilo G, Oreto G. Citalopram - induced long WT syndrome and torsades de pointes: role for concomitant therapy and disease. Int J Cardiol 2011; 148(2):226-8. doi: 10.1016/j.ijcard.2009.05.060 PMID: 19540606
10. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of torsades de pointes. Dtsch Arztebl Int 2011; 108(41):687-93. doi: 10.3238/arztebl.2011.0687 PMID: 22114630
11. Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992; 53(Suppl):61-6.
12. Edwards JG, Goldie A, Papayanni-Papasthatis S. Effect of paroxetine on the electrocardiogram. Psychopharmacology 1989; 97(1):96-8. PMID: 2523548
13. Kuhs H, Rudolf GA. Cardiovascular effects of paroxetine. Psychopharmacology, 1990; 102(3):379-82. PMID: 2147517
14. Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013; 346:f288. doi: 10.1136/bmj.f288 PMID: 23360890
15. Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother 2013; 47(10):1330-41. doi: 10.1177/1060028013501994 PMID: 24259697
16. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiogram in an independent risk factor for sudden death due to cardiac arrest. Circulation 1991; 83(6):1888-94. PMID: 2040041
17. Zhang Y, Post WS, Dalal D, Blasco-Colmenares E, Tomaselli GF, Guallar E. QT-interval duration and mortality rate: results from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2011; 171(19):1727-33. doi: 10.1001/archinternmed.2011.433 PMID: 22025428
18. Sala M, Lazzaretti M, De Vidovich G, Caverzasi E, Barale F, d'Allio G, et al. Electrophysiological changes of cardiac function during antidepressant treatment. Ther Adv Cardiovasc Dis 2009; 3(1):29-43. doi: 10.1177/1753944708096282 PMID: 19124389
19. Food US and Administration Drug. FDA drug safety communication: Abnormal heart rhythms associated with high doses of Celexa. 2011. Available: http://www.fda.gov/drugs/drugsafety/ucm269086.htm (accessed 20 April 2014).
20. Food US and Administration Drug. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. 2012. Available: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm (accessed 20 April 2014).
21. Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considertations for older adults. Am J Geriatr Pharmacother 2012; 10(4):264-71. doi: 10.1016/j. amjopharm.2012.05.002 PMID: 22683398
22. Canada Health. Celexa (citalopram)-Association with abnormal heart rhythms - For Health Professionals. 2012. Available: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/14672a-eng.php (accessed 21 March 2015).
23. Zivin K, Pfeiffer PN, Bohnert AS, Ganoczy D, Blow FC, Nallamothu BK, et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40mg. Am J Psychiatry 2013; 170(6):642-50. doi: 10.1176/appi.ajp.2013.12030408 PMID: 23640689
24. Lam RW. Psychopharmacology for the clinician (antidepressants and QT prolongation). J Psychiatry Neurosci 2013; 38(2):E5-6. doi: 10.1503/jpn.120256
25. Howland RH. A critical evaluation of the cardiac toxicity of citalopram: part 2. J psychosoc Nurs Ment Health Serv 2011; 49(12):13-16. doi: 10.3928/02793695-20111102-04 PMID: 22085614
26. van Haelst IM, van Klei WA, Doodeman HJ, Warnier MJ, De Bruin ML, Kalkman CJ, et al. QT interval prolongation in users of selective serotonin reuptake inhibitors in an elderly surgical population: a cross sectional study. J Clin Psychiatry 2014; 75(1):15-21. doi: 10.4088/JCP.13m08397 PMID: 24345304
27. Leonard CE, Bilker WB, Newcomb C, Kimmel SE, Hennessy S. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf 2011; 20(9):903-913. doi: 10. 1002/pds.2181 PMID: 21796718
28. Uchida M, Spencer AE, Biederman J, Castro VM, Kenworthy T, Chan J, et al. A systematic evaluation of the QTc interval and antidepressants in youth: An electronic health record study. J Dev Behav Pediatr. 2015; 36(6):434-9. doi: 10.1097/DBP.0000000000000188 PMID: 26154713
29. Weeke P, Jensen A, Folke F, Gisalson GH, Olesen JB, Andersson C, et al. Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Clin Pharmacol Ther. 2012; 92 (1):72-9. doi: 10.1038/clpt.2011.368 PMID: 22588605
30. Canada Health. Antidepressant Cipralex (escitalopram): Updated information regarding dose-related heart risk. 2012. Availbel: http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/13674a-eng.php (accessed 21 March 2015).
31. Canada Statistics, Government of Canada Statistics Canada. http://www.statcan.gc.ca/tablestableaux/sum-som/l01/cst01/demo31a-eng.htm (accessed 01 October 2014).
32. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. BMJ 2007; 335(7624):806-8. PMID: 17947786
33. Levy AR, O'Brien BJ, Sellors C, Grootendorst P,Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003; 10(2):67-71. PMID: 12879144
34. Li DQ, Kim R, McArthur E, Fleet JL, Bailey DG, Juurlink D, et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. CMAJ 2015; 187(3):174-80. doi: 10.1503/cmaj.140950 PMID: 25534598
35. Weir MA, Beyea MM, Gomes T, Juurlink DN, Mamdani M, Blake PG, et al. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med 2011; 171(7):703-4. doi: 10.1001/archinternmed. 2011.103 PMID: 21482850
36. Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA 2013; 310(23):2544-53. doi: 10.1001/jama. 2013.282426 PMID: 24346990
37. Shih AW, Weir MA, Clemens KK, Yao Z, Gomes T, Mamdani MM, et al. Oral bisphosphonate use in the elderly is not associated with acute kidney injury. Kidney Int. Nature Publishing Group 2012; 82 (8):903-8.
38. Zhao YY, Weir MA, Manno M, Cordy P, Gomes T, Hackamm DG, et al. New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann Intern Med 2012; 156(8):560-9. doi: 10. 7326/0003-4819-156-8-201204170-00003 PMID: 22508733
39. Jain AK, Cuerden MS, McLeod I, Hemmelgam B, Akbari A, Tonelli M, et al. Reporting of the estimated glomerular filtration rate was associated with increased use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers in CKD. Kidney Int 2012; 81(12):1248-53. doi: 10.1038/ki. 2012.18 PMID: 22437415
40. Patel AM, Shariff S, Bailey DG, Juurlink DN, Gandhi S, Mamdani M, et al. Statin toxicity from macrolide antibiotic co-prescription: A population-based cohort study. Ann Intern Med 2013; 158(12):869-76. doi: 10.7326/0003-4819-158-12-201306180-00004 PMID: 23778904
41. Isbister GK, Friberg LE, Duffull SB. Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose. Intensive Care Med 2006; 32(7):1060-5. PMID: 16791669
42. Friberg LE, Isbister GK, Duffull SB. Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. Br J Clin Pharmacol 2006; 61(2):177-90. PMID: 16433872
43. Hennessy S, Leonard CE, Freeman CP, Deo R, Newcomb C, Kimmel SE, et al. Validation of diagnostic codes for outpatient originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data. Pharmacoepidemiol Drug Saf 2010; 19(6):555-62. doi: 10.1002/pds.1869 PMID: 19844945
44. Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying ventricular arrhythmias using administrative and claims data. Pharmacoepidemiol Drug Saf, 2012; 21 (Suppl1):148-153.
45. De Bruin ML, van Hemel NM, Leufkens HG, Hoes AW. Hospital discharge diagnosis of ventricular arrhythmias and cardiac arrest were useful for epidemiologic research. J Clin Epidemiol 2005; 58 (12):1325-9. PMID: 16291479
46. Quan H, Li B, Saunders LD, Nilsson CI, Alibhai A, Ghali WA, et al. Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health Serv Res 2008; 43(4):1424-41. PMID: 18756617
47. Jha P, Deboer D, Sykora K, Naylor CD. Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. J Am Coll Cardiol 1996; 27(6):1335-42. PMID: 8626941
48. Austen PC. An introduction to propensity score methods for reducing the effect of confounding in observational studies. Multivariate Behav Res 2011; 46(3):399-424. PMID: 21818162
49. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: A Monte Carlo study. Stat Med 2007; 26(4):734-53. PMID: 16708349
50. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol 2006; 163(12):1149-56. PMID: 16624967
51. Joffe MM, Ten Have TR, Feldman HI, Kimmel SE. Model selection, confounder control, and marginal structural models: Review and new applications. Am Stat 2004; 58(4):272-79.
52. Austen P. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Comm Statist Simulation Comput 2009; 38(6):1228-34.
53. Fleet JL, Dixon SN, Shariff SZ, Quinn RR, Nash DM, Harel Z, et al. Detecting chronic kidney disease in population-based administrative databases using an algorithm of hospital encounter and physician claim codes. BMC Nephrol 2013; 14:81. doi: 10.1186/1471-2369-14-81 PMID: 23560464
54. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998; 52(6):377-84. PMID: 9764259